Clinical trials
Chronic Liver Disease clinical trials
Below are recruiting chronic liver disease clinical trials, each written for real people, not researchers. We’re tracking 402 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06571474Recruiting
Fat Cell Function in Obesity and Metabolism Study
This study looks at how a type of immune cell (macrophage) in fat tissue processes lipids, and how that affects metabolism in people with different body weights. It may help us understand why some people with obesity develop diabetes and fatty liver while others do not.
Columbia, MissouriAges 18–70 - NCT06585982Recruiting
Synbiotics for MAFLD: gut health and liver fat study
This trial tests whether taking a synbiotic (a mix of helpful bacteria and fiber) can improve insulin levels and reduce inflammation in people with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). It may help by changing the balance of bacteria in your gut.
Semarang, SemarangAges 25–55 - NCT06920043RecruitingPhase 2
Study of a new drug for cirrhosis from fatty liver disease
This trial tests a new medication (efimosfermin alfa) for people with cirrhosis (liver scarring) caused by MASH, a type of fatty liver disease. It aims to see if the drug can help improve liver health.
Chandler, ArizonaAges 18–75 - NCT06701825RecruitingPhase 4
Genetic testing before tacrolimus in kidney transplant
This study tests whether doing a simple genetic test before starting the anti-rejection drug tacrolimus can lead to better dosing and outcomes in kidney transplant patients. It also looks at whether this approach is cost-effective.
Madrid, MadridAges Any age - NCT06707129Recruiting
New criteria to see if NASH liver scarring has reversed
This study is creating better ways to measure if liver scarring from NASH (a type of fatty liver disease) has improved. It may help doctors know if treatments are working.
Beijing, Beijing MunicipalityAges 18–70 - NCT07403604RecruitingPhase 1
Lowering Insulin to Reduce Fat Buildup in the Liver
This study tests if lowering insulin levels can reduce fat buildup in the liver for people with a fatty liver condition called MASLD. It's looking for adults who are overweight and have early signs of insulin resistance but not diabetes.
New York, New YorkAges 18–65 - NCT06781242Recruiting
Genes and symptoms in inherited bile flow problems
This study looks at how genes affect bile flow problems in the liver. If you have a rare genetic condition like PFIC, researchers want to understand your specific type better by comparing your genes to your symptoms.
Bologna, BolognaAges 18 years+ - NCT06820970Recruiting
Combined therapy for heart artery blockages that weren't fully opened
This trial tests if combining a new heart procedure with a special type of therapy called mindfulness therapy can help prevent heart problems in people with coronary artery disease that could not be fully fixed with stents or surgery.
Zhengzhou, HenanAges 18 years+ - NCT06890169Recruiting
One-stop telehealth program for weight and diabetes
This trial tests a telehealth program that helps people lose weight and manage type 2 diabetes and fatty liver disease at the same time. It's a one-stop remote clinic that combines medical advice, nutrition, and lifestyle support.
SingaporeAges 21–70 - NCT07022197RecruitingPhase 1/Phase 2
BAFF-R CAR T cells for severe nerve and immune diseases
This trial tests a new treatment using your own immune cells (called BAFF-R CAR T cells) for people with severe nerve and immune diseases that have not improved with standard medicines. These cells are designed to target and destroy certain immune cells that may be causing your illness.
Tianjin, Tianjin MunicipalityAges 18–60 - NCT07143968RecruitingPhase 2
Resmetirom for people with MASLD and HIV
This study tests if resmetirom can help people who have both HIV and a liver condition called MASLD (fat buildup in the liver not caused by alcohol). You may qualify if your liver has a certain amount of fat and stiffness, and your HIV is well controlled with stable medication.
Birmingham, AlabamaAges 18 years+ - NCT07198854Recruiting
Stem cell treatment for liver failure in hepatitis B patients
This trial looks at how well stem cell (MSC) treatment works for people with severe liver failure caused by hepatitis B. It checks what factors affect the success of the treatment.
Guangzhou, GuangdongAges 18 years+ - NCT07237750Recruiting
Weight loss trial: endoscopy procedure vs lifestyle changes
This study compares a new endoscopic procedure (a stomach tightening treatment done through a tube in your mouth) with a structured diet and exercise program to help with weight loss. It is for Asian adults who have tried and failed to lose weight before.
Beijing, Beijing MunicipalityAges 18–65 - NCT07358546RecruitingPhase 1
Test of efimosfermin alfa in adults with liver problems
This trial is for adults with liver cirrhosis (scarring) who have moderate to severe liver impairment. It studies how the body handles a new medicine called efimosfermin alfa, to see if it could be a safe treatment option. You may be able to join if your liver function is stable and you fall into a specific Child-Pugh class.
Rialto, CaliforniaAges 18–70 - NCT07374042RecruitingPhase 3
A supplement to protect muscle in advanced kidney disease
This trial tests whether a special diet supplement (Ketoanalogue) can help protect your muscles while you follow a moderate protein diet. It is for people with chronic kidney disease stage 4 or 5 who are not on dialysis or have not had a kidney transplant.
Clermont-FerrandAges 18–100 - NCT00345930Recruiting
Study of liver injury after medicines or supplements
This study looks at people (including children over age 2) who develop liver injury that may be caused by a drug or a complementary/alternative medicine (CAM) product. It helps doctors better understand what causes the injury and how to evaluate it.
Los Angeles, CaliforniaAges 2 years+ - NCT03224949Recruiting
Study comparing fatty liver types and healthy livers
This study compares liver samples and blood tests from people with alcohol-related fatty liver disease, alcohol-related hepatitis, and cirrhosis (including some with liver cancer) against healthy controls. It aims to better tell these liver conditions apart and understand what is different between them.
Cleveland, OhioAges 18–75 - NCT07378072Recruiting
12-week daytime eating study for fatty liver in obesity
This study tests if restricting eating to daytime hours for 12 weeks can reduce liver fat in people with obesity. It aims to help those with fatty liver disease improve their health without medication.
AngersAges 18–65 - NCT07662902Enrolling by invitation
Gut Barrier Study in Ulcerative Colitis Remission
This study looks at gut barrier function in people with ulcerative colitis who are in remission. It uses a non-invasive liver test to check for subtle changes in the body.
ZagrebAges 18–70 - NCT06895018Enrolling by invitation
Grape Drink Trial for Diabetes and Fatty Liver
This study tests a drink made from grape pomace (a natural byproduct) that is rich in polyphenols—compounds that may help the liver and heart. Participants have type 2 diabetes and mild fatty liver, and researchers want to see if the drink improves liver health, blood sugar, and gut bacteria over several months.
NaplesAges 35–70 - NCT07288905Recruiting
Exercise with blood flow restriction for healthy people and CKD patients
This study tests if combining exercise with blood flow restriction training (BFRT) is safe and helpful for healthy adults and people with chronic kidney disease (CKD). It aims to improve strength and health without heavy weights.
TainanAges 20–85 - NCT04442334Recruiting
European registry for people with fatty liver
This registry collects health and lifestyle information from adults with suspected or confirmed fatty liver (NAFLD) to help researchers better understand the condition. You may be asked about diet, exercise, alcohol intake, and some liver-related tests.
AntwerpAges 18–100 - NCT04819217Recruiting
Probiotics and a toxin binder to slow chronic kidney disease
This trial studies an oral product (a “uremic toxin” absorber) plus probiotics to help slow the progression of chronic kidney disease. It may help by lowering harmful gut-related substances that can build up when kidney function is reduced.
TaipeiAges 20 years+ - NCT07343778RecruitingPhase 3
Safety of Hydronidone Capsules for Liver Scarring and Cirrhosis
This study tests a new medication called Hydronidone for people with liver scarring (fibrosis) or cirrhosis. It aims to see if the drug is safe and may help slow or improve the condition.
ZhengzhouAges 18 years+
Hear when a new Chronic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic liver disease?
- Yes. Clin2 currently lists 402 recruiting chronic liver disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic liver disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic liver disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.